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Abstract 
Pancreatic ductal adenocarcinoma has the worst prognosis of any cancer. New 
adjuvant chemotherapies are urgently required, which are well tolerated by patients 
with unresectable cancers. This paper reviews the existing proof of concept data 
namely: laboratory, pharmacoepidemiological, experimental medicine and clinical trial 
evidence for investigating metformin in patients with pancreatic ductal 
adenocarcinoma. Laboratory evidence shows metformin inhibits mitochondrial ATP 
synthesis which directly and indirectly inhibits carcinogenesis. Drug-drug interactions 
of metformin with proton pump inhibitors and histamine H2-receptor antagonists may 
be of clinical relevance and pertinent to future research of metformin in pancreatic 
ductal adenocarcinoma. To date, most cohort studies have demonstrated a positive 
association with metformin on survival in pancreatic ductal adenocarcinoma, although 
there are many methodological limitations with such study designs. From experimental 
medicine studies, there is a sparse data in humans. The current trials of metformin 
have methodological limitations. Two small randomized controlled trials (RCTs) 
reported null findings, but there were potential inequalities in cancer staging between 
groups and poor compliance with the intervention. Proof of concept data, 
predominantly from laboratory work supports assessing metformin as an adjunct for 
pancreatic ductal adenocarcinoma in RCTs. Ideally more experimental medicine 
studies are needed for proof of concept. However, many feasibility criteria need to be 
answered before such trials can progress.  
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Introduction 
Pancreatic ductal adenocarcinoma (PDAC) has the worst prognosis of any cancer with 
an overall 5-year survival of less than 5%, which has remained relatively unchanged 
for several decades.[1] Worldwide, there are 337,872 new cases diagnosed annually, 
with the incidence similar to the mortality.[1] Surgical resection remains the sole 
potential curative treatment, although this is only possible in up to 10% of patients who 
have localized tumors.[2] Those with unresectable PDAC are referred for palliative and 
supportive care with, interventions focused on symptom control. Palliative 
chemotherapy with gemcitabine helps alleviate symptoms but gives only a minimal 
survival benefit, of only 1 month.[2] A more recent chemotherapy regime, 
FOLFIRINOX, which consists of: oxaliplatin, irinotecan, fluoruracil and leucovorin,  
increases the median overall survival time to 11.1 months, compared to 6.8 months in 
patients prescribed gemcitabine (p<0.001).[3] For both chemotherapies, particularly 
FOLFIRINOX, a good medical performance status is required. New chemotherapies 
are now urgently required, which are well tolerated by many patient groups, to increase 
survival times for those with this aggressive cancer. A possibility is the oral 
hypoglycemic drug metformin, due to its emerging additional anti-cancer properties as 
demonstrated in laboratory experiments. 
The purpose of this paper is to review the evidence required to justify the conduct of 
well-designed RCTs assessing metformin as a treatment in patients with inoperable 
PDAC. Although several clinical trials have already investigated metformin and 
reported no benefits, we argue these had methodological and clinical limitations which 
may have masked any potential benefits of the drug. We suggest further trials, 
addressing these deficiencies, are now required to more fully assess metformin as a 
potential chemotherapeutic agent. The feasibility questions which must first be 
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answered before commencing such trials are also discussed. The article then 
progresses to review the potential anti-cancer molecular mechanisms of metformin 
and the pharmacoepidemiological data assessing associations with its use and 
survival which justify the conduct of further trials. 
Methodology 
For this narrative review, we searched PubMed using the MESH terms “Metformin” 
and “Pancreatic Neoplasms”, pharmacoepidemiological studies and clinical trials 
investigating metformin use and survival in PDAC. The references of papers were 
reviewed to identify additional papers not found in the initial search. Clinical trials 
currently being undertaken were identified from ClinicalTrials.gov. A further search 
identified randomized controlled trials investigating metformin in cancers at other 
anatomical sites.  
Randomized controlled trials 
To date, to the best of our knowledge, there have only been two reported RCTs which 
assessed metformin as a potential adjunctive treatment in patients with inoperable 
PDAC. In the largest, from the Netherlands, 202 patients were screened for eligibility 
in 4 hospitals of which; 81 (40%) were ineligible or withdrew their consent. Therefore, 
121 patients were randomized to receive either: gemcitabine/erlotinib plus oral 
metformin (n=60) (metformin 500mg twice daily in the first week, escalated to 1000mg 
twice daily thereafter) or gemcitabine/erlotinib and placebo (n=61).[4] The exclusion 
criteria included: previous metformin use within 6 months before enrolment, borderline 
resectable cancer, WHO performance status ≥3 and liver enzymes >5.0 times the 
upper limit of normal due to liver metastases. In the intention to treat analysis, there 
was no statistically significant difference in overall survival at six months between the 
 
 
5 
 
two groups (median 7·6 vs 6.8 months, log-rank test p=0.78, HR 1.06, 95% CI 0.72-
1.55). However, there were several reasons which may affect the validity of this null 
finding. Firstly, there were large differences in the baseline tumor marker CA19-9 
levels between the metformin and placebo groups. In the active arm, the median 
CA19-9 (kU/l) was 561 (IQR = 112-6319) but the level was lower in the control arm at 
245 (IQR 21-2118, no p-value quoted). CA19-9, although it has poor sensitivity, may 
reflect tendency to progression. CA19-9 can be falsely negative in patient groups with 
a negative Lewis blood group (Le α-β-) antigen phenotype, which is approximately 5-
10% of the population.[5,6] However it is possible that more patients allocated 
metformin had more cancers with a tendency to progress than those who received 
placebo. This imbalance may mean any potential benefit of the drug went undetected 
if the metformin group had proportionately more advanced cancers.  
Secondly, in the metformin arm, 22% of patients (n=13) discontinued the drug because 
of a higher proportion of side effects namely: vomiting (43% vs 25%), severe diarrhea 
(10% vs 5%) and anorexia (37% vs 20%, no p-values quoted). Therefore, more 
patients stopped metformin than placebo (22% vs 13% p=0.21). In the intention-to-
treat analysis, again this may mask any potential therapeutic benefit of metformin if 
the drug was not actually tolerated and absorbed. The authors did not report a per 
protocol analysis, namely one in patients who tolerated the drug. Whether these 
symptoms are side effects of metformin itself or representative of the underlying 
cancer itself are uncertain, particularly as there were more aggressive cancers in the 
active drug arm. Symptoms, such as vomiting, could be due to PDAC itself, for 
example if the cancer invades the duodenal wall giving upper gastrointestinal tract 
obstruction. If so, the drug is less likely to reach the small intestine where it is 
absorbed. Furthermore, steatorrhea may occur due to pancreatic enzyme insufficiency 
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initiated by exocrine destruction of the gland by the cancer. Lastly, patients in the 
placebo arm received a median of five (IQR 2.0–6.0) cycles of chemotherapy, but only 
three (IQR 2.0–6.0) cycles in the metformin group (p=0·05).  Doses of placebo were 
reduced less often than metformin (28% vs 57% of patients, respectively, p=0·002). 
Additionally, doses of placebo were escalated more frequently than metformin (80% 
vs 63% of patients, p=0·044). These dose alterations would also bias the results 
towards the null. The calculated effect size to be detected was perhaps unrealistically 
high, namely a 6-month overall survival absolute benefit of 25% with 120 patients.  
A second and open-label, single center, prospective, smaller randomized phase II trial 
of 60 patients conducted in Italy, investigated metformin in combination with a 
chemotherapy regime of: cisplatin, epirubicin, capecitabine and gemcitabine (PEXG), 
versus PEXG alone, in patients with metastatic PDAC.[7] Here 70 patients were 
screened for eligibility and 86% (n=60) were randomized. In total, 31 patients were 
allocated to the PEXG and metformin (2g oral daily) arm, with 29 to the control one 
prescribed PEXG and placebo. Again, several baseline variables were incomparable 
between the two groups, namely CA19-9 levels and cancer stage. Here, the median 
CA19-9 (IU/mL), although not statistically significantly different, was almost half in the 
metformin arm (457, IQR 33-1962) than in the control one (863, IQR 113-1473) 
(p=0.66). More patients in the control arm had lung metastasis than in the active one 
(24% vs 6.5%, p=0.08). The primary end point was cancer progression-free survival 
(PFS) at six months, defined as no evidence of radiological progression or death. In 
the intention-to-treat analysis, median PFS for the metformin and control arms were 
4.9 months vs 6.1 months respectively (HR 2.0, 95% CI 1.05–3.8; p=0.036) with no 
difference in the median overall survival between the metformin and control arms (10.4 
months vs 6.8 months (HR 0.92, 95% CI 0.54-1.56)). The trial was powered assuming 
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a baseline PFS of 50% at 6 months, and >70% for the metformin one. To detect this 
large effect size 78 patients were required (39 per treatment arm) so the trial only 
recruited 77%, of those required to detect this large effect size. The significance level 
used was 10% i.e. a 10% chance of detecting a false positive result, which is above 
conventional full statistical significance. This relatively small sample size and the 
imbalances in characteristics between groups mean definitive conclusions on 
metformin’s efficacy cannot be reached. The authors reported there were no 
differences in grade 3 or 4 toxic effects in the patients assigned metformin. Grade 3 
adverse events are classed as severe, but not immediately life-threatening events 
requiring hospitalization, and grade 4 adverse events have life threatening 
consequences. The authors did not report the frequency of less serious grade 1 or 2 
toxic events, although they state only two patients withdrew IMP due to drug-related 
side effects. Additionally, the authors made no comment on why the trial was open-
label, and not double-blinded.  
For both these trials we assessed bias using the Cochrane risk of bias tool (Table 1). 
This consists of seven domains of methodology to minimize bias namely: random 
sequence generation, allocation concealment, blinding of participants and personnel, 
blinding of outcome assessment, incomplete outcome data, selective reporting and 
other bias. For each domain, the assessor assigns a judgement of high or low risk of 
bias. If there is not sufficient evidence available, an unclear risk of bias is allocated. 
Both trials had some inherent biases present when assessed. The Netherlands trial 
had 2 domains identified as high risk of bias, namely incomplete outcome data and 
other bias. The Italian study had 3 domains which were high risk namely, blinding of 
participants and personnel, blinding of outcome assessment and other bias.  
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To conduct a large RCT which addresses the limitations inherent in the previous trials, 
feasibility work must be performed to answer unknowns to both justify and inform the 
planning of such a large interventional study. Feasibility work must record the 
proportion of the study population already prescribed metformin at diagnosis, who 
would be ineligible for randomization, the prevalence of drug side effects and other 
drugs which may affect its pharmacokinetics. These will help guide planning for the 
sample size calculations and recruitment into future, large RCTs; considering the drop-
out rate during the trial period.  
In summary, the null findings from both these RCTs must be interpreted with caution 
and future trials must address their limitations. As the randomization led to inequalities 
of cancer staging distribution in opposite directions and both showed no effect of 
metformin, these could reflect the true result. However, there is another possibility that 
these inequalities lead to incorrect findings. Larger sample sizes are needed so there 
are no inequalities in the cancer stages between the two arms, and measures 
incorporated to ensure drugs are not discontinued. These trials could progress 
informed by the proof of concept data discussed later for assessing metformin as an 
adjunctive therapy in PDAC. 
The pharmacokinetics and pharmacodynamics of metformin 
An appreciation of the absorption, metabolism, excretion and actions of metformin is 
important for developing clinical trials of its use. The biguanide, metformin (N, N-
dimethylbiguanide), is a drug commonly prescribed for the management of patients 
with type 2 diabetes mellitus (T2DM). Discovered in 1922, it was introduced in clinical 
medicine to treat diabetes in France in 1957[8] and is now on the list of the World 
Health Organization (WHO) essential medicines.[9] Although metformin is generally 
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well tolerated, common side effects include gastrointestinal symptoms, namely 
nausea, vomiting and diarrhea. Rarely, but more seriously, lactic acidosis can occur, 
which is more likely with existing underlying renal disease.[10]  
The absorption of metformin in the small intestine is primarily mediated by the plasma 
membrane monoamine transporter (PMAT) and organic cation transporter 3 
(OCT3).[11,12] OCTs are molecules in the membrane themselves that facilitate 
movements of endogenous substrates such as creatinine and dopamine into cells.[13] 
Metformin is not metabolized in the body and has a half-life of approximately 5 
hours.[14]. The uptake into hepatocytes is mediated by OCT1 and to a lesser extent 
by OCT3[14], whereas renal uptake is by OCT 2.[15] Metformin is excreted unchanged 
through the kidney.[14] Drugs that inhibit these membrane transporters may therefore 
be clinically relevant. In vitro studies suggested that PPIs inhibit OCT1, OCT2 and 
OCT3, subsequently raising plasma levels of metformin.[16] This, at first, appears 
paradoxical as metformin absorption in the intestine would be inhibited. However, it is 
more likely the effect of PPIs in reducing hepatic absorption of metformin via OCT1 
overrides that of reduced intestinal absorption.[12,16] As metformin’s passage into 
hepatocytes is reduced, this may be clinically relevant as the potential anti-cancer 
action of metformin may occur through inhibition of hepatic gluconeogenesis. 
Furthermore, the histamine H2-receptor antagonist, cimetidine, through reducing the 
renal tubular secretion of metformin, increases plasma levels of metformin.[17]  
Genetic factors may influence the efficacy of metformin. Approximately 35% of 
patients prescribed metformin monotherapy for T2DM will fail to achieve optimal 
glycemic control and require additional hypoglycemic drugs.[18-21] This heterogeneity 
is partly due to genetic factors resulting in variation of plasma metformin levels, a 
phenomenon known as pharmacogenomics. Genome-wide association research 
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which investigated the variability in clinical response to metformin identified the 
potential responsible genes,[22,23] including the SNP rs11212617 at a locus 
containing the ataxia telangiectasia mutated gene (ATM).[24,25] The minor allele C of 
ATM is required for metformin action in the liver by upregulating AMPK activation.[22] 
More recently, studies have shown ATM also mediates uptake of metformin by hepatic 
transporters, in particular OCT1.[26,27] Those with minor allele C may therefore 
respond better to metformin, which is present in 44% of people.[28] Investigating such 
genes is required to potentially augment metformin’s therapeutic actions and mitigate 
its adverse ones. Such work is relevant to PDAC, to ascertain which patients may best 
respond to metformin. 
Proof of concept  
Support for evaluating metformin in appropriately designed RCTs is informed by proof 
of concept data. This may be derived from: i) laboratory studies, ii) epidemiological 
data, iii) experimental medicine studies in patients, and iv) large RCTs of metformin in 
other cancers.  
Proof of concept 1: Biological plausibility of metformin as an adjunctive 
chemotherapeutic drug demonstrated in laboratory studies 
Metformin may be beneficial in patients with PDAC firstly due to its direct inhibitory 
effects on cancer cells themselves, and secondly its indirect actions by lowering blood 
glucose through inhibiting hepatic gluconeogenesis and increasing glucose utilization 
in skeletal muscle. A lower blood glucose leads to less potentially mitogenic excess 
insulin being secreted from pancreatic islet cells and then stimulating cell division.[29] 
Firstly, metformin may exert direct anti-cancer effects on cells themselves by inhibiting 
mitochondrial ATP synthesis. This promotes cancer cell death as there is then 
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insufficient energy for anabolic processes, such as structural protein formation.[30,31] 
Metformin inhibits complex 1 in the mitochondria, so ATP production decreases, which 
then increases both cellular AMP:ATP and ADP:ATP ratios which activates the 
enzyme AMPK.[32] The potential anti-cancer properties of stimulating AMPK are the 
inhibition of macromolecule synthesis necessary for cell growth and division.[33,34] 
AMPK also inhibits the mechanistic target-of-rapamycin complex (mTORc) which is 
responsible for activating numerous cellular pathways, including protein 
translation.[35,36] AMPK inhibits mTOR through phosphorylation of the Tuberous 
Sclerosis Complex 2 (TSC2).[35] These cellular processes are summarized in figure 
1. Secondly the possible indirect anti-cancer effects of metformin are through reducing 
secretion of insulin. Excess insulin is mitogenic which may be particularly relevant to 
pancreatic carcinogenesis, as the hormone is synthesized in, and released from the 
pancreas itself.[37] Mitogenesis is stimulated by upregulation and activation of the 
Ras-Raf-mitogen-activated protein (MAP) kinase signaling pathway.[38] Metformin 
through activating AMPK reduces plasma glucose and consequently mitogenic insulin 
levels.  
In vitro work shows metformin exerts anti-tumor properties on pancreatic cancer cell 
lines, including inhibiting cell proliferation and apoptosis in a dose-dependent 
manner.[39] Metformin down-regulates transcription factors (pancreatic duodenal 
homeobox-1 (PDX-1)) which are related to PDAC.[40] More recently, metformin, when 
combined with gemcitabine, enhanced the induction of pancreatic cancer cell 
apoptosis and inhibited cellular proliferation both in vitro and in vivo.[41] A limitation of 
the current chemotherapy drugs is that drug resistant tumor cells develop, likely 
mediated by tumor initiation cells (cancer stem cells).[42,43] Metformin inhibited the 
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function of such CD44+/CD2410 cells and these actions were enhanced when the drug 
was an adjunct to doxorubicin.[44,45] 
Laboratory studies assessing the potential anti-cancer effects of metformin have been 
extensive, but not exclusive to PDAC. In vitro studies have investigated numerous 
cancers, including: breast,[46-49] prostate,[50] endometrial[51] and brain.[52] The 
dosages of metformin used were much higher than those prescribed in clinical 
practice. Nevertheless, there is some laboratory evidence in breast cancer of anti-
cancer properties within the normal therapeutic dosage (6μM–30μM) for patients 
taking metformin for T2DM.[47] In breast cancer cells, a further pathway of action of 
the possible anti-cancer effects of metformin has been recognized. Breast cancer cells 
overexpressing human epidermal growth factor receptor 2 (HER2) were inhibited by 
metformin through direct inhibition of p70S6K1 enzyme activity, independent of the 
AMPK pathway.[53] p70S6K1 activity is responsible for protein synthesis and cell 
proliferation and is a downstream target for mTOR.[54] In vivo studies in transgenic 
mice demonstrated metformin delayed the growth of breast cancer, reduced tumor 
size [55] and delayed tumor onset,[56] with similar findings in lung cancer and 
colorectal cancer.[57,58] In conclusion, these laboratory-based studies provide 
supportive proof of concept information that metformin merits investigation in further 
trials in PDAC.  
Proof of concept 2: Pharmacoepidemiological evidence 
Further RCTs of metformin would be supported by pharmacoepidemiological studies 
showing its use is associated with increased survival times in patients with PDAC after 
diagnosis, compared to those not prescribed metformin. The observational study 
design chosen is crucial when appraising the validity of the findings of such work. A 
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prospective study design would be the most robust, however a further three themes 
must be considered when assessing the validity of pharmacoepidemiological studies 
namely: consideration of time-related biases, the choice of reference groups and 
completeness for data collection on drug use.  
i. In pharmacoepidemiological studies assessing post-diagnosis metformin use 
mitigating against several time-related biases is vital, as if not considered these 
may lead to spurious over-estimates of the potential benefits of metformin. 
Immortal time bias is the misclassification of exposed person-time for metformin 
users. This occurs when exposure time is incorrectly recorded from the date of 
diagnosis rather than that of the first drug prescription, which may be much later 
after diagnosis. This bias leads to an overestimate of the length of metformin 
prescription. The second bias, time window bias, is commoner in retrospective 
work where participants, taking and not taking metformin have not been matched 
according to similar durations of the exposure time for potentially receiving the 
drug. Patients prescribed metformin may have lived longer due to the less 
aggressive tumors and therefore be more likely to have had the opportunity to be 
prescribed metformin. The association with the increased survival and metformin 
is therefore due to the more favorable prognosis of the cancer rather than 
metformin itself. The ideal pharmacoepidemiological study would consider both 
time-related biases in their methodology and analysis. 
ii. A difficulty with interpreting pharmacoepidemiological studies investigating oral 
hypoglycemic drugs in PDAC is related to the choice of the reference group i.e. the 
non-metformin users. One could infer either a potential beneficial effect for 
metformin, if there is no effect on cancer survival with the reference group i.e. firstly 
T2DM patients prescribed an alternative oral hypoglycemic drug such as a 
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sulfonylurea, or secondly patients with PDAC but not T2DM. Using both these 
groups have potential methodological problems. Hypothetically, drugs such as 
sulfonylurea could worsen survival as they stimulate insulin release from the 
pancreas, which in excess is mitogenic.[59] Therefore, an alternative explanation 
to a beneficial effect of metformin is actually a detrimental one of sulfonylureas, if 
there is actually no effect of metformin. Using a reference group without T2DM may 
be problematic if diabetes itself affects survival.  
iii. A further methodological problem is due to the short survival times of most patients 
with inoperable PDAC and how post-diagnosis medication is recorded from the 
drug databases. When patients are admitted to hospital, the primary care 
prescription records are incomplete, as the admitting hospital dispense the 
medications during admission. These interruptions inherent in the primary care 
records compromise the validity of the data, particularly if the patient has multiple 
hospital admissions.  
Therefore, limitations of the methodology of such pharmacoepidemiological work are 
potentially large, hence they are difficult to interpret if all these areas are not 
considered.  
In total, 11 retrospective cohort and 1 prospective cohort study were identified (table 
two). The prospective cohort investigation of 44 patients reported null findings for 
metformin use (HR 0.70, 95% CI 031-1.59 p=0.39). In the 11 retrospective cohort 
studies (cohort size range 237-3393), 7 reported statistically significant associations 
for metformin use improving survival in PDAC. The other 4 reported null findings, 
although 3 documented statistically significant results in subgroup analyses.  
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Four studies did clearly define metformin exposure and their actions to mitigate against 
time-related biases,[60-63] however most were unclear when addressing such bias. 
Only two studies performed analyses investigating post-diagnostic metformin use, 
although this was not the primary outcome for any of these.[61,62] Of these, one 
investigation reported for patients with locally advanced disease a HR for survival 0.75, 
95% CI 0.58-0.97 (p=0.03).[61,64] These would be the more relevant studies to justify 
a trial, where metformin use after diagnosis is investigated. Therefore, the profound 
difficulties with conducting pharmacoepidemiological work in this area mean that 
generally they should not be used for proof of concept assessment. 
The effect of metformin, according to gender, and risk of PDAC was reported in a well-
designed case-control study conducted in the United Kingdom, although this 
investigated etiology rather than treatment.[65] The authors documented a reduction 
in the risk of PDAC associated with those receiving long term metformin prescriptions 
in women (adjusted OR 0.43 (95% CI 0.23-0.80)) but not in men (adjusted OR 1.59 
(95% CI 0.95-2.66)). The authors did not suggest a possible mechanism for this 
finding. In a univariate analysis, estrogens were not associated with risk of developing 
PDAC. In the 12 cohort studies discussed above, none reported a difference of effect 
of metformin, according to gender, and survival in PDAC. If a mechanism can be 
elucidated, evaluating responses to metformin in RCTs would be informative. 
Proof of concept 3: Experimental medicine  
Experimental medicine studies are those conducted in patients which may investigate 
tumor markers suggestive of a potential therapeutic benefit, rather than the primary 
outcome itself, such as survival. In a sub-group analysis, in the trial from the 
Netherlands, the overall survival was longer in patients with higher trough 
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concentrations of metformin (>1.0mg/L) after the first cycle of chemotherapy (median 
overall survival 9.1 months, vs 6.1 months, HR=0.37 (95%CI 0.14-0.98); log-rank 
p=0.049).[4] Also, patients in the metformin arm with a decrease in insulin 
concentrations had a longer overall survival than those without (median overall 
survival 18.6 months versus 5.7 months, HR=0.20 (95% CI 0.06-0.60), p=0.004). 
Importantly, the authors did not comment on if the cancer stages were similar in the 
two arms in these analyses. In patients who actively absorb metformin there may be 
a true survival benefit, although alternatively there may be significant patient selection 
biases. For example, patients with less aggressive and localized cancers, may be 
better able to ingest and absorb metformin than those with more advanced lesions. 
Therefore, a less advanced cancer stage, rather than the metformin itself may be 
associated with these improved survival times.  
In the Italian trial, the authors investigated changes in baseline biomarkers in 35 of 60 
(58%) patients who completed five cycles of treatment. After excluding patients with 
inadequate blood samples, 14 (48%) patients in the control arm and 12 (39%) patients 
in the metformin arm were included in the analysis. Patients who received metformin 
had a decrease in mean insulin of -11 pmol/L after cycle 5 compared to baseline 
(p=0.12), but in the control arm insulin increased by 7 pmol/L (p=0.22). The Italian trial 
also reported the frequency of the minor allele C of the ATM gene, namely 11% (CC), 
54% (AC) and 35% (AA). In the metformin arm, patients with the C allele had the 
highest reduction in fasting plasma glucose after 1 month of treatment (CC -2.19 ±1.44 
mmol/L (p=0.05), AC -0.94 ±1.46 mmol/L (p=0.05), AA -0.87 ±2.1 mmol/L (p=0.25)). 
No significant change in glucose was observed in the control arm.  
A phase II trial registered in Canada (NCT02978547) is investigating the effects of 
neoadjuvant metformin on tumor cell proliferation and progression in resection 
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specimens. Patients receive metformin 500mg twice daily for a minimum of 7 days 
prior to surgery. Laboratory biomarkers (fasting glucose, insulin, GGT, HOMA index, 
plasma ctDNA and transcriptomic sequencing) will be assessed at baseline, before 
surgery and 2-3 months after surgery. This trial is due to start recruiting in 2019 and 
the results will add to the experimental medicine evidence. Other such work is 
required, particularly in patients with unresectable PDAC, for human experimental 
proof of concept information. Such work should consider changes in CA19-9 and other 
relevant clinical biomarkers, as well as genomic markers such as the C allele of the 
ATM gene.  
Proof of concept 4: Metformin in other cancers 
Further proof of concept data is if metformin is shown to be of benefit in clinical trials 
in other cancers. Metformin in the chemoprevention of colorectal cancer was 
investigated in a randomized phase 3 double-blind, placebo-controlled Japanese trial 
in preventing recurrent colorectal adenomas or hyperplastic polyps in 151 patients, 
without diabetes, who previously underwent polypectomy.[66] Patients in the 
treatment arm received 250mg metformin daily for one year. After one year, 
colonoscopies were repeated to assess the number and prevalence of recurrent 
adenomas or polyps. The prevalence of adenomas was significantly lower in the 
metformin group compared to the placebo (30.6 vs 51.6%) one (RR 0.60, 95% CI 0.39-
0.92).  
In post-menopausal women, 60 patients with hormone receptor positive locally 
advanced or metastatic breast cancer were randomly allocated an aromatase inhibitor 
(letrozole or exemestane) plus oral metformin 500mg twice daily (n=30) or placebo 
(n=30).[67] For 80% power, at least 30 patients in each arm were required to detect 
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an extra 1.38 months survival one year after diagnosis in median PFS. PFS was similar 
between the two groups, (median PFS 4.7 vs 6.0 months in the metformin vs placebo 
arms respectively (HR 1.2, 95% CI 0.7-2.1 p=0.48)). The median follow-up was 22.3 
months. There are limitations with the interpretation of these null findings, as this trial 
was a small open-label phase II trial. Recruitment rate into the trial was not reported 
so generalizability could not be assessed.  
There are currently 14 registered clinical trials that are actively following up, but no 
longer recruiting participants in other cancer sites namely: lung, gynecological, breast, 
prostate and hematological. There are 87 registered trials (ClinicalTrials.gov) in the 
recruitment stage of a trial, again across many cancer sites. 
On-going trials of metformin in PDAC and feasibility work 
Currently, there are several clinical trials in progress investigating metformin as an 
adjuvant or monotherapy in PDAC. Six are registered on ClinicalTrials.gov with 1 yet 
to commence recruitment, 3 currently recruiting, and 2 with follow-up but now not 
recruiting (table three). Three of these are in patients with resectable cancers and the 
remainder with metastatic cancer, although only 2 are assessing overall survival 
(death from any cause) as an outcome. The first is a double blinded, phase II RCT in 
China, currently recruiting 300 participants (NCT02005419). The patient population 
underwent curative resection, with adjuvant metformin prescribed for 28 days post-
operatively. The second trial, in the United States, is investigating metformin as an 
adjuvant therapy in patients with metastatic disease (NCT01666730).  
Conclusions 
The role of metformin as an adjuvant chemotherapy in patients with PDAC remains 
unclear. However, there is substantial laboratory evidence for biological mechanisms 
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for anti-cancer effects of the drug. The interpretation of findings from 
pharmacoepidemiology and RCTs remains difficult due to limitations in their study 
design and conduct. Further large clinical trials, which address these limitations are 
required. However, before these are started, ideally further experimental medicine 
studies should be conducted to provide proof of concept data, and if so the feasibility 
of large RCTs first addressed. 
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Table one: Cochrane risk of bias assessment tool [68] 
Trial 1: Metformin in patients with advanced pancreatic cancer: a double-blind, 
randomized, placebo-controlled phase 2 trial. [4] 
Bias Authors’ 
judgement 
Support for judgement 
 
Random 
sequence 
allocation 
(Selection 
bias) 
Low Hospital pharmacy staff randomly assigned patients in a 
1:1 ratio by computer-generated permuted-block 
randomization (block size of six), to receive gemcitabine 
and erlotinib with either placebo or metformin. The 
allocation sequence was generated by the TENALEA 
Clinical Trial Data Management System (Amsterdam, 
Netherlands) 
Allocation 
concealment 
(Selection 
bias) 
Low The allocation sequence was generated by the 
TENALEA Clinical Trial Data Management System 
(Amsterdam, Netherlands) and was held by the hospital 
pharmacist, who assigned the patients to treatment. 
Patients, physicians, and study personnel were masked 
to treatment allocation which was concealed by keeping 
block size confidential. 
Blinding of 
participants 
and 
personnel 
(Performance 
bias) 
Low Patients, physicians, and study personnel were masked 
to treatment allocation. 
Blinding of 
outcome 
assessment 
(Detection 
bias) 
Low The unmasked data became available to the 
investigators after the final database lock (July 22, 2014). 
Incomplete 
outcome 
data 
(Attrition 
bias) 
High In the metformin arm, 58 participants discontinued (34 
with tumor progression, 13 toxic effects, 3 deaths and 8 
withdrew consent). 
In the placebo arm, 59 participants discontinued (42 had 
tumor progression, 8 toxic effects, 2 deaths and 7 
withdrew consent). 
Selective 
reporting 
(Reporting 
bias) 
Unclear The study protocol is available and endpoints in protocol 
matches published study outcome measures. One 
discrepancy is that the published trial states, “Following 
a protocol amendment, we measured the plasma 
metformin trough concentrations in a subset of patients 
(n=61) at day 8 of cycle one and day 1 of cycle two.” 
Published protocol states, “assessments on day 1 every 
cycle: metformin levels, biomarkers” There is no 
explanation for this protocol amendment. 
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Other bias High “Patients received a median of five (IQR 2·0–6·0) 
treatment cycles in the placebo group and three (2–6) 
cycles in the metformin group (p=0·050). 
Doses of placebo were reduced less often than those of 
metformin (17 [28%] of 61 patients vs 34 [57%] of 60 
patients, respectively, p=0·0020), and placebo doses 
were escalated more frequently than those of metformin 
(49 [80%] vs 38 [63%] patients; p=0·044)” Patients in 
placebo arm received more cycles of chemotherapy than 
those in the metformin group.  
Baseline CA19-9 levels were different between the two 
arms. As the sample size is small, randomization may not 
lead to equal distribution of characteristics between the 
two arms.  
Trial 2: (Ir)relevance of Metformin Treatment in Patients with Metastatic 
Pancreatic Cancer: An Open-Label, Randomized Phase II Trial.[7] 
Random 
sequence 
allocation 
(Selection 
bias) 
Unclear “After signing the informed consent, patients were 
randomly allocated to receive the PEXG regimen with 
(arm A) or without (arm B) the addition of metformin.” No 
further information reported regarding randomization. 
Allocation 
concealment 
(Selection 
bias) 
Unclear “After signing the informed consent, patients were 
randomly allocated to receive the PEXG regimen with 
(arm A) or without (arm B) the addition of metformin.” No 
further information reported regarding randomization. 
Blinding of 
participants 
and 
personnel 
(Performance 
bias) 
High Open label (unblinding) 
Blinding of 
outcome 
assessment 
(Detection 
bias) 
High Open label (unblinding) 
Incomplete 
outcome 
data 
(Attrition 
bias) 
Low In the metformin arm, 17 (55%) participants discontinued 
(12 with radiological progression, 3 clinical progression, 
1 toxic death and 1 withdrew consent). 
In the placebo arm, 14 (48%) participants discontinued 
(11 with radiological progression, 2 clinical progression 
and 1 medical decision). Therefore, withdrawal rates 
proportionate between the two groups were similar.  
Selective 
reporting 
(Reporting 
bias) 
Low The study protocol is available, and the endpoints match 
published study outcome measures.  
 
Other bias High The trial was powered assuming a baseline progression-
free survival (PFS) of 50% at 6 months, and >70% for the 
metformin arm. This primary analysis required 78 
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patients (39 per treatment arm) so the sample size was 
too small to detect this effect size. The significance level 
used was 10% i.e. a 10% chance of detecting a false 
positive result, which is above conventional full statistical 
significance.  
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Table two: Summary of pharmacoepidemiological studies for metformin and survival in PDAC 
First author, year 
published, country 
Study type Total 
Participants  
Exposure group Reference group Outcome measure(s) 
HR, 95% CI (p-value) 
Chaiteerakij R, 
2016, United 
States[61] 
Retrospective 
cohort 
980 Ever use of metformin 
(n=366) Pre-diagnosis 
 
 
 
 
 
 
 
Metformin exposure after 
PDAC diagnosis (n=85) 
Never use of metformin 
(n=614) 
 
 
 
 
 
 
 
0.92, 0.79-1.08 (p=0.30) 
 
Resectable cancers; 
0.84, 0.62-1.15 (p=0.29) 
Locally advanced; 
0.75, 0.58-0.97 (p=0.03)* 
Metastatic cancers; 
1.19, 0.93-1.54 (p=0.17) 
 
Metformin naïve at diagnosis; 
1.04, 0.78-1.39 (p=0.77) 
Currie CJ, 2012, 
United 
Kingdom[62] 
Retrospective 
cohort 
112,408 
PDAC 
(n=2308) 
Metformin use 90 days 
before diagnosis 
(n=2308) 
 
Metformin use ≤90 days 
immediately after 
diagnosis (n=1142) 
Non-diabetic cohort 
(n=104016) 
 
 
Never use of metformin 
(n=2173) 
1.26, 0.85-1.85 (p=0.25) 
 
 
 
0.65, 0.38-1.11 (p=0.12) 
Kozak MM, 2016, 
United States[69] 
Retrospective 
cohort 
171 Ever use of metformin 
(n=18) Pre-diagnosis 
Never use of metformin 
(n=153) 
0.42, 0.30-0.94 (p=0.04)* 
Lee SH, 2016, 
South Korea[70] 
Retrospective 
cohort 
237 Ever use of metformin 
(n=117) Pre-diagnosis 
Never use of metformin 
(n=120) 
0.61, 0.46-0.81 (p<0.001)* 
Sadeghi N, 2012, 
United States[64] 
Retrospective 
cohort 
302 Ever use of metformin 
(n=117) Pre-diagnosis 
 
Never use of metformin 
(n=185) 
 
0.64, 0.48-0.86 (p=0.003)* 
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* indicates statistical significance 
Metformin use >2 years 
(n=26) 
Metformin use <2 years 
(n=47) 
Metformin use (yrs) 
2-5; 0.51, 0.28-1.05 (p=0.07) 
>5; 0.82, 0.40-1.69 (p=0.59) 
Choi Y, 2015, 
Korea[71] 
Retrospective 
cohort 
349 
(T2DM 
n=183) 
Ever use of metformin in 
T2DM (n=56) 
 
Ever use of metformin in 
full cohort 
Pre-diagnosis 
Never use of metformin  0.69, 0.49-0.98 (p=0.04)* 
 
 
0.70, 0.49-0.99 (p=0.04)* 
Hwang AL, 2013, 
United 
Kingdom[72] 
Retrospective 
cohort 
516 Ever use of metformin 
(n=247) Pre-diagnosis 
Never use of metformin 
(n=269) 
1.11, 0.89-1.38 (p=0.37) 
Jo A, 2015, South 
Korea[73] 
Retrospective 
cohort 
764 Ever use of metformin 
(n=530) Pre-diagnosis 
Never use of metformin 
(n=234) 
0.73, 0.61-0.87 (p<0.001)* 
Frouws MA, 2017, 
The 
Netherlands[63] 
Retrospective 
cohort 
907 Ever use of metformin 
(n=77) Pre-diagnosis 
Never use of metformin 
(n=830) 
 
Sulfonylurea use (n=43) 
Adjusted OR, 95% CI 
0.86, 0.66-1.12 (p= 0.26) 
 
Adjusted OR, 95% CI 
0.86, 0.50-1.46 (p=0.57) 
Amin S, 2016, 
United States[74] 
Retrospective 
cohort 
1916 Ever use of metformin 
(n=1098) Pre-diagnosis 
Never use of metformin 
(n=818) 
0.88, 0.81-0.96 (p<0.01)* 
 
Cerullo M, 2016, 
United States[60] 
Retrospective 
cohort 
3393 Ever use of metformin 
(n=456) Pre-diagnosis 
 
Metformin dose 
<1000mg/day (n=254) 
Metformin dose 
≥1000mg/day (n=173) 
Never use of metformin 
(n=2937) 
 
 
 
 
0.79, 0.57-0.93 (p<0.005)* 
 
 
0.80, 0.65-0.98 (p=0.03)* 
0.70, 0.53-0.92 (p=0.01)* 
Ambe CM, 2016, 
United States[75] 
Prospective 
cohort 
44 Ever use of metformin 
(n=19) Pre-diagnosis 
Never use of metformin 
(n=25) 
0.70, 0.31-1.59 (p=0.39) 
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Table three: Summary of trials registered on ClinicalTrials.gov 
Title Total 
participants 
Randomi
zation 
Treatment arm Primary 
outcome 
Status End 
date 
Resectable PDAC       
A Pilot Trial of Stereotactic Body 
Radiation Therapy and Metformin for 
Borderline-Resectable and Locally-
Advanced Pancreatic Adenocarcinomas 
(NCT02153450) 
15 
 
 
No Metformin PO daily or BID on 
days -11 to -1. Stereotactic 
radiosurgery 5 days a week for 5 
weeks and receive concurrent 
metformin PO BID for 5 weeks. 
Laparotomy on week 6 (or weeks 
5-7). 
Dose-
limiting 
toxicity 
(DLT) rate  
Recruiting Oct 
2018 
A Phase II, Randomized, Double-blind, 
Placebo Controlled Study to Evaluate 
the Efficacy and Safety of the 
Combination of Gemcitabine and 
Metformin in Treating Patients With 
Pancreatic Cancer After Curative 
Resection (NCT02005419) 
300 Yes Gemcitabine at 1000 mg/m2 on 
days 1, 8, and 15; metformin at 2 
g on days 1-28 
 
Recurrence-
free survival  
Recruiting June 
2017 
The Effects of Neoadjuvant Metformin 
on Tumor Cell Proliferation and Tumor 
Progression in Pancreatic Ductal 
Adenocarcinoma (NCT02978547) 
20 No Metformin 500 mg PO BID for at 
least 7 days, until 2 days prior to 
surgery. 
Tumor cell 
proliferation  
Not yet 
recruiting 
Jan 
2021 
Unresectable PDAC       
A Pilot Study of Gemcitabine, Abraxane, 
Metformin and a Standardized Dietary 
Supplement (DS) in Patients With 
Unresectable Pancreatic Cancer 
(NCT02336087) 
21 No Gemcitabine and paclitaxel 
albumin-stabilized nanoparticle 
formulation IV on days 1, 8, and 
15. Metformin PO BID day -6 and 
dietary supplement PO BID day -
3. Repeat every 28 days  
Compliance, 
toxicity and 
feasibility 
Recruiting Sept 
2018 
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A Phase II Study of Metformin Plus 
Modified FOLFOX 6 in Patients With 
Metastatic Pancreatic Cancer 
(NCT01666730) 
50 No Metformin PO BID on days 1-14 
and FOLFOX therapy comprising 
leucovorin, fluorouracil and 
oxaliplatin IV on day 1. Repeat 
every 14 days  
Median 
overall 
survival 
Active, not 
recruiting 
Mar 
2018 
An Exploratory Study of Metformin With 
or Without Rapamycin as Maintenance 
Therapy After Induction Chemotherapy 
in Subjects With Metastatic Pancreatic 
Adenocarcinoma (NCT02048384) 
22 
 
Yes Metformin + rapamycin Arm B 
patients will receive 850mg orally 
twice a day and rapamycin 4mg 
orally once a day on a 28-day 
cycle. 
Safety and 
feasibility  
Active, not 
recruiting 
Dec 
2019 
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Table four: Summary of findings of the review 
Proof of concept 1: Biological plausibility of metformin as an adjunctive 
chemotherapeutic drug demonstrated in laboratory studies 
 The potential anti-cancer effects of metformin are through AMPK activation 
and reduction of circulating insulins levels, which in excess are mitogenic. 
Proof of concept 2: Pharmacoepidemiological evidence 
 Interpretation of findings from pharmacoepidemiological studies in PDAC 
should be cautious given biases. 
 To date, most cohort studies have demonstrated a positive association with 
metformin on survival in PDAC, in particular those with locally advanced 
disease. 
Proof of concept 3: Experimental medicine 
 In the Netherlands trial, overall survival was longer in patients with higher 
trough concentrations of metformin and in those with decreased insulin 
concentrations. 
Proof of concept 4: Metformin in other cancers 
 Metformin has a chemoprevention role in colorectal cancer in preventing 
colorectal adenoma recurrence. 
 There are many trials underway in other cancers. 
Future work required 
 In order to inform and justify a future large RCT, further experimental 
medicine studies are required. 
 Such trials would need to investigate the significance of PPIs, genetic 
variants and degree of hepatic metastases.  
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Figure One: Potential anti-cancer effects of metformin. Metformin inhibits complex 
1 of the mitochondria and reduces ATP production. A reduction of ATP consequently 
activates AMPK and inhibits processes involved in cell growth and cell division. ┴, 
inhibitor arrow. ↑, activator arrow. LKB1, Liver kinase B1; AMPK, AMP-activated 
protein kinase; TSC, Tuberous sclerosis complex; mTOR, Mechanistic target of 
rapamycin.  
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